- Trials with a EudraCT protocol (263)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (4)
263 result(s) found for: Eye examination.
Displaying page 1 of 14.
EudraCT Number: 2021-003005-21 | Sponsor Protocol Number: cloROP-2021 | Start Date*: 2021-12-10 |
Sponsor Name:Region Örebro län | ||
Full Title: Klonidin as pain relief in eye examination of premature infants - cloROP | ||
Medical condition: Pain during eye examination of premature infants. | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-005694-31 | Sponsor Protocol Number: 2012/ADE002 | Start Date*: 2013-07-05 | |||||||||||
Sponsor Name:Adenovir Pharma AB | |||||||||||||
Full Title: Evaluation of the Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Acute Phase Adenoviral-Induced Epidemic Keratoconjunctivitis (EKC). A Randomised, Double-Masked, Placebo-Controlled, Mult... | |||||||||||||
Medical condition: Acute phase Adenoviral-induced Epidemic Keratoconjunctivitis, EKC | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004271-12 | Sponsor Protocol Number: NGF0213 | Start Date*: 2014-01-17 | |||||||||||
Sponsor Name:Dompé s.p.a | |||||||||||||
Full Title: An open-label study evaluating safety and efficacy of recombinant human nerve growth factor (rhNGF) eye drops at different doses in patients with Dry Eye | |||||||||||||
Medical condition: Dry Eye syndrome is caused by either decreased tear production or increased tear film evaporation. Dry eye is a chronic inflammatory condition of the ocular surface with severe symptoms and visual ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005621-30 | Sponsor Protocol Number: 541 | Start Date*: 2008-07-03 | |||||||||||
Sponsor Name:BAUSCH&LOMB | |||||||||||||
Full Title: A multicenter, Investigator - masked, parallel-group, randomized study of the efficacy and safety of loteprednol etabonate 0.5% eyedrops versus dexamethasone 0.1% eyedrops in the treatment of ocula... | |||||||||||||
Medical condition: Subjects scheduled to undergo cataract surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000937-54 | Sponsor Protocol Number: MC2-03-C1 | Start Date*: 2015-08-03 | ||||||||||||||||
Sponsor Name:DRUG DELIVERY SOLUTIONS ApS (PART OF MC2 BIOTEK GROUP) | ||||||||||||||||||
Full Title: A phase II, multicenter, randomized, double-masked, 4 parallel arms, controlled 6-month trial designed to evaluate the safety and efficacy of PAD ciclosporin (CsA 0.06% and 0.03%) ophthalmic disper... | ||||||||||||||||||
Medical condition: ocular dryness (Dry Eye Disease - DED) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) DK (Completed) NO (Completed) AT (Completed) ES (Completed) PT (Completed) FR (Completed) SK (Completed) CZ (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-007872-40 | Sponsor Protocol Number: ROPP-2008-01 | Start Date*: 2014-08-19 | |||||||||||
Sponsor Name:Premacure AB, A member of the Shire Group of Companies | |||||||||||||
Full Title: Determination of the rhIGF-I/rhIGFBP-3 Dose; Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-I Levels within Physiological Levels in Premature Infan... | |||||||||||||
Medical condition: Retinopathy of Prematurity (ROP) | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (Completed) IT (Completed) NL (Prematurely Ended) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-005160-18 | Sponsor Protocol Number: RP101-200 | Start Date*: 2018-12-18 | |||||||||||
Sponsor Name:Redwood Pharma AB | |||||||||||||
Full Title: A Phase II, multicentre, randomised, placebo-controlled, double-masked trial of RP101 ophthalmic formulation versus vehicle in post-menopausal women with moderate to severe dry eye syndrome | |||||||||||||
Medical condition: moderate or severe dry eye syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: AT (Completed) HU (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001708-19 | Sponsor Protocol Number: SVS20-EUR-06-01 | Start Date*: 2008-02-21 | |||||||||||
Sponsor Name:TRB CHEMEDICA INTERNATIONAL SA | |||||||||||||
Full Title: A 3-month study of the efficacy and safety of SVS20 in patients with bilateral moderate dry eye syndrome : A prospective, double-masked, randomised, controlled, parallel-group, 3-arm, multicentre, ... | |||||||||||||
Medical condition: treatment on bilateral moderate dry eye syndrome due to Sjögren's syndrome or diagnosed as a primary syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003253-36 | Sponsor Protocol Number: LBS-008-CT03 | Start Date*: Information not available in EudraCT |
Sponsor Name:Belite Bio, Inc | ||
Full Title: Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects | ||
Medical condition: Stargardt Disease | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004857-15 | Sponsor Protocol Number: SYL1001_III | Start Date*: 2015-05-07 |
Sponsor Name:Sylentis | ||
Full Title: DOSE-FINDING STUDY TO ASSESS THE SAFETY AND EFFECT OF SYL1001 IN PATIENTS WITH OCULAR PAIN | ||
Medical condition: Patients with eye pain associated to dry eye | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) EE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-002823-46 | Sponsor Protocol Number: LT4030-201 | Start Date*: 2018-09-11 | |||||||||||
Sponsor Name:Laboratoires THÉA; Research and Development Department | |||||||||||||
Full Title: Efficacy and safety assessment of T4030 eye drops (unpreserved fixed combination of bimatoprost 0.01% and timolol 0.1% or 0.5%) versus Ganfort® UD (Unit Dose) in ocular hypertensive or glaucomatous... | |||||||||||||
Medical condition: Glaucoma, ocular hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) PL (Completed) HU (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002439-14 | Sponsor Protocol Number: SHP640-301 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Shire Human Genetic Therapies, Inc. | |||||||||||||
Full Title: A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine... | |||||||||||||
Medical condition: Adenoviral Conjunctivitis | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) EE (Prematurely Ended) HU (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) AT (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000747-27 | Sponsor Protocol Number: 049/SI | Start Date*: 2020-09-09 | |||||||||||
Sponsor Name:SOCIETÀ INDUSTRIA FARMACEUTICA ITALIANA (SIFI) SPA | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase II Study to evaluate the Safety and Efficacy of Pro-ocular™ 0.5% and 1% in Patients with Dry Eye Syndrome | |||||||||||||
Medical condition: Dry Eye is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film and accompanied by ocular symptoms, in which tear film instability, hyperosmolarity... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002910-29 | Sponsor Protocol Number: BECRO/PHN/LATANO | Start Date*: 2017-09-26 | |||||||||||||||||||||
Sponsor Name:PHARMATHEN | |||||||||||||||||||||||
Full Title: Therapeutic Equivalence (non-inferiority), Randomized, Observer-blind, two Parallel Group, Clinical Trial for Comparing the Efficacy and Tolerability of a new Generic Preservative-Free Formulation ... | |||||||||||||||||||||||
Medical condition: Open angle glaucoma or ocular hypertension. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-004524-29 | Sponsor Protocol Number: BECRO/PHN/LATIM | Start Date*: 2018-02-28 | |||||||||||||||||||||
Sponsor Name:PHARMATHEN | |||||||||||||||||||||||
Full Title: Therapeutic Equivalence (non-inferiority), Randomized, Observer-blind, two Parallel Group, Clinical Trial for Comparing the Efficacy and Tolerability of a new Generic Preservative-Free Formulation ... | |||||||||||||||||||||||
Medical condition: Open angle glaucoma or ocular hypertension. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-017388-41 | Sponsor Protocol Number: LT1225-PII-06/09 | Start Date*: 2010-01-14 |
Sponsor Name:Laboratoires Théa | ||
Full Title: Efficacy and Safety Assessment of Azyter® eye drops (T1225) in patients with blepharitis | ||
Medical condition: Patients with blepharitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000465-17 | Sponsor Protocol Number: CHL.3-02-2019 | Start Date*: 2020-06-16 | |||||||||||
Sponsor Name:Sintetica S.A. | |||||||||||||
Full Title: A Phase II/III, Randomized, Double-Masked, Vehicle-Controlled, Efficacy, Safety and Tolerability Study of Chloroprocaine 3% Gel Eye Drops in healthy volunteers | |||||||||||||
Medical condition: healthy volunteers | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000182-31 | Sponsor Protocol Number: CHDR1438 | Start Date*: 2015-02-11 |
Sponsor Name:CHDR | ||
Full Title: A randomized, double-blind, placebo-controlled, cross-over study to assess the effects of fampridine on eye movements and nerve conduction in patients with multiple sclerosis (MS) and a unilateral ... | ||
Medical condition: Multiple sclerosis (MS) and a unilateral or bilateral internuclear ophthalmoplegia (INO) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004409-42 | Sponsor Protocol Number: LRP/LUBT010/2016/008 | Start Date*: 2020-11-23 | |||||||||||
Sponsor Name:Lupin Limited (Biotechnology Division) | |||||||||||||
Full Title: A Global, Phase III, Double Blind, Randomized Controlled Study to Compare the Efficacy, Safety & Immunogenicity of LUBT010 with Lucentis® in Patients with Neovascular Age-Related Macular Degeneration | |||||||||||||
Medical condition: Neovascular Age Related Macular Degeneration (AMD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005486-13 | Sponsor Protocol Number: 12-EI-0134 | Start Date*: 2013-02-25 | |||||||||||
Sponsor Name:The National Eye Institute | |||||||||||||
Full Title: A Phase II Randomized Study to Compare Anti-VEGF Agents in the Treatment of Diabetic Macular Edema (CADME) | |||||||||||||
Medical condition: Diabetic Macular Edema (DME) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
